Regulatory Guide 2026

    IFRS S2 + NIS B-1 for Health & Pharma in Mexico: 2026 Guide

    BMV and BIVA issuers face the unique challenge of simultaneously complying with IFRS S2 (CNBV) and NIS B-1 (CINIF) for the same fiscal year, implying two regulatory frameworks, two regulators, and potentially two external assurance processes. Without a centralized platform, companies end up with sustainability and finance teams operating in silos, collecting redundant data in non-auditable spreadsheets. The overlap between IBSO indicators and IFRS S2 metrics is significant but not total, requiring precise mapping.

    The pharmaceutical/health sector is the only one in Mexico with specific sectoral environmental regulation (NOM-087 RPBI) that must integrate with the 30 IBSO indicators of NIS B-1 — a sector where CINIF and SEMARNAT regulate the same waste stream with different formats and reporting deadlines.

    Why IFRS S2 + NIS B-1 Applies Differently in Health & Pharma

    CFO and Sustainability Director of BMV-listed healthcare and pharmaceutical companies

    Companies in this sector:Genomma LabMédica SurHospital ABCFEMSA Salud

    Biological-Infectious Hazardous Waste (RPBI) — classification, weight, and final disposal required by NOM-087-SEMARNAT/SSA1-2002 that must align with NIS B-1 hazardous waste indicators

    Pharmaceutical cold chain — energy consumption of refrigeration chambers at -2°C to -8°C and ultra-freezing at -80°C without sub-metering by product type or batch

    Scope 3 Cat 1 for imported active pharmaceutical ingredients (APIs) — suppliers in India/China without carbon footprint data per API or production batch

    Medical gases (nitrous oxide N2O — potent GHG with GWP 298) used in anesthesia without recovery systems in Mexican hospitals

    Critical IFRS S2 + NIS B-1 KPIs for Health & Pharma

    Required KPIData SourceDifficulty
    RPBI generated per occupied bed-day (kg/bed-day)Purchased electricity (Scope 2)High 🔴
    Energy consumption per equivalent surgical procedure (kWh/procedure)Electricity bills (Scope 2)High 🔴
    Water intensity per hospital bed or per pharmaceutical product unitCat 1 - APIs e ingredientes farmacéuticos importadosHigh 🔴
    Percentage of pharmaceutical waste with certified final disposal (%)HR / payroll systemMedium 🟡
    N2O emissions per anesthetic procedure (kgCO2e/procedure)ERP / accounting systemMedium 🟡

    Hard-to-Collect Data in Health & Pharma

    RPBI weight by category (infectious, pathological, sharps, pharmaceutical) — many Mexican hospitals do not disaggregate by category for NIS B-1 reporting

    N2O consumption in anesthetic procedures per operating room (requires integration with medical gas management system)

    Emission factor of imported APIs by supplier/country of origin for Scope 3 Cat 1

    That is why manual Excel-based processes will not pass the 2027 assurance. Without automated traceability, an external auditor cannot verify the completeness or accuracy of emissions data.

    Checklist: 8 Steps to Comply with IFRS S2 + NIS B-1 in Health & Pharma

    1. 1

      Mapping and reconciliation of all 30 IBSO indicators with IFRS S2 metrics requirements to avoid duplication of effort

    2. 2

      Unified GHG emissions data collection for Scope 1, 2, and 3 serving both frameworks simultaneously without double measurement

    3. 3

      Management of two distinct assurance processes: CNBV's limited assurance under IFRS S2 and CINIF's review under NIS B-1, ideally with the same auditor

    4. 4

      Alignment of reporting calendars — the integrated sustainability report must meet both deadlines from a single data collection cycle

    5. 5

      Implementation of robust internal controls over sustainability information capable of supporting third-party assurance under both frameworks from 2027

    6. 6

      Connect data sources (ERP, meters, suppliers) to a centralized platform

    7. 7

      Review with internal audit team and adjust consolidation perimeter

    8. 8

      Generate report in CNBV/CINIF format ready for external assurance

    How Climatta Automates IFRS S2 + NIS B-1 for Health & Pharma

    Automated Collection

    Eliminate spreadsheets in Health & Pharma. Climatta connects your systems and automatically collects RPBI generated per occupied bed-day and other critical KPIs.

    Auditor-Grade Traceability

    Every data point has source, date, and owner documented. The 2027 assurance auditor can trace every figure to its origin in your systems.

    IFRS S2 + NIS B-1 Report Ready

    Generates the report in the exact CNBV + CINIF format — tables, metrics, and narrative. No last-minute manual reformatting.

    Onboarding in 4 Weeks

    Climatta connects to Health & Pharma systems in 4 weeks. No months-long IT project or external implementation consultant.

    FAQ: IFRS S2 + NIS B-1 in Health & Pharma

    Yes. The pharmaceutical/health sector is the only one in Mexico with specific sectoral environmental regulation (NOM-087 RPBI) that must integrate with the 30 IBSO indicators of NIS B-1 — a sector where CINIF and SEMARNAT regulate the same waste stream with different formats and reporting deadlines.

    The first report covers FY2025 and must be submitted in 2026 to CNBV + CINIF. Aseguramiento limitado IFRS S2 + revisión NIS B-1 desde 2027.

    IFRS S2 + NIS B-1 requires: Mapping and reconciliation of all 30 IBSO indicators with IFRS S2 metrics requirements to avoid duplication of effort; Unified GHG emissions data collection for Scope 1, 2, and 3 serving both frameworks simultaneously without double measurement; Management of two distinct assurance processes: CNBV's limited assurance under IFRS S2 and CINIF's review under NIS B-1, ideally with the same auditor. For Health & Pharma, the most critical are: RPBI generated per occupied bed-day (kg/bed-day), Energy consumption per equivalent surgical procedure (kWh/procedure), Water intensity per hospital bed or per pharmaceutical product unit.

    Issuers that fail to submit the IFRS S2 + NIS B-1 report to CNBV + CINIF in 2026 face formal observations, potential suspension of stock exchange operations, and reputational damage with ESG investors. Aseguramiento limitado IFRS S2 + revisión NIS B-1 desde 2027.

    With Climatta, typical onboarding for Health & Pharma takes 4–8 weeks: 2 weeks connecting to existing systems, 2 weeks validating historical data, and 2–4 weeks generating the pilot report in CNBV + CINIF format.

    Ready to comply with IFRS S2 + NIS B-1 in Health & Pharma?

    Climatta centralizes all data collection, generates the report in regulatory format, and leaves it ready for 2027 external assurance. No spreadsheets.